Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
1,628
datasets available to search
ShareScore release 0.9.0
Dataset results
1,628 results for “type safety”
A Study to Evaluate the Effect of Dapagliflozin on Blood Glucose Level and Renal Safety in Patients With Type 2 Diabetes
ClinicalTrials.gov study NCT02413398. IPD Sharing: Not stated. Countries: 8. Publications: 2.
A Study Comparing the Effects and Safety of Dulaglutide With Insulin Glargine in Type 2 Diabetes Mellitus
ClinicalTrials.gov study NCT01648582. IPD Sharing: YES. Countries: 4. Publications: 8.
Efficacy and Safety of Oral Semaglutide Using a Flexible Dose Adjustment Based on Clinical Evaluation Versus Sitagliptin in Subjects With Type 2 Diabetes Mellitus.
ClinicalTrials.gov study NCT02849080. IPD Sharing: YES. Countries: 10. Publications: 7.
Safety and Efficacy of Oral Semaglutide Versus Dulaglutide Both in Combination With One OAD (Oral Antidiabetic Drug) in Japanese Subjects With Type 2 Diabetes
ClinicalTrials.gov study NCT03015220. IPD Sharing: YES. Countries: 1. Publications: 5.
Efficacy and Safety of Faster-acting Insulin Aspart Compared to NovoRapid® Both in Combination With Insulin Degludec in Children and Adolescents With Type 1 Diabetes
ClinicalTrials.gov study NCT02670915. IPD Sharing: Not stated. Countries: 18. Publications: 1.
Efficacy and Safety of Oral Semaglutide Versus Empagliflozin in Subjects With Type 2 Diabetes Mellitus
ClinicalTrials.gov study NCT02863328. IPD Sharing: Not stated. Countries: 12. Publications: 8.
Efficacy and Safety of Liraglutide in Combination With Insulin Therapy Compared to Insulin Alone in Japanese Subjects With Type 2 Diabetes
ClinicalTrials.gov study NCT01572740. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Efficacy and Safety of FIAsp Compared to Insulin Aspart Both in Combination With Insulin Detemir in Adults With Type 1 Diabetes
ClinicalTrials.gov study NCT01831765. IPD Sharing: Not stated. Countries: 9. Publications: 6.
Dose-response Study of Efficacy and Safety of Botulinum Toxin Type A to Treat Spasticity of the Leg(s) in Cerebral Palsy
ClinicalTrials.gov study NCT01893411. IPD Sharing: Not stated. Countries: 14. Publications: 2.
GLP-1 Receptor Agonist Lixisenatide Versus Exenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin
ClinicalTrials.gov study NCT00707031. IPD Sharing: Not stated. Countries: 18. Publications: 2.
A Study to Investigate the Efficacy and Safety of RG7774 in Patients With Diabetes Mellitus Type 1 or Type 2 With Treatment-Naive Diabetic Retinopathy
ClinicalTrials.gov study NCT04265261. IPD Sharing: YES. Countries: 7. Publications: 1.
Phase Ib/II Study of Efficacy and Safety of MEK162 and Panitumumab, in Adult mCRC Patients With Mutant or Wild-type RAS Tumors
ClinicalTrials.gov study NCT01927341. IPD Sharing: YES. Countries: 7. Publications: 1.
Efficacy and Safety of Dapagliflozin in Combination With Glimepiride (a Sulphonylurea) in Type 2 Diabetes Patients
ClinicalTrials.gov study NCT00680745. IPD Sharing: Not stated. Countries: 7. Publications: 3.
A Trial to Evaluate the Safety, Efficacy, and Tolerability of Brexpiprazole in Treating Agitation Associated With Dementia of the Alzheimer's Type
ClinicalTrials.gov study NCT03548584. IPD Sharing: YES. Countries: 1. Publications: 7.
Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Arm After a Stroke
ClinicalTrials.gov study NCT01392300. IPD Sharing: Not stated. Countries: 7. Publications: 3.
Efficacy and Safety of Semaglutide Once Weekly Versus Insulin Glargine Once Daily as add-on to Metformin With or Without Sulphonylurea in Insulin-naïve Subjects With Type 2 Diabetes
ClinicalTrials.gov study NCT02128932. IPD Sharing: Not stated. Countries: 15. Publications: 12.
Efficacy and Safety of Empagliflozin (BI 10773) Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 Diabetes
ClinicalTrials.gov study NCT01177813. IPD Sharing: Not stated. Countries: 9. Publications: 4.
Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes and Moderate Renal Impairment
ClinicalTrials.gov study NCT02827708. IPD Sharing: YES. Countries: 8. Publications: 7.
An Examination of the Blood Pressure Lowering Ability and Safety of Olmesartan Medoxomil in Patients With Type II Diabetes
ClinicalTrials.gov study NCT00403481. IPD Sharing: Not stated. Countries: 1. Publications: 3.
GLP-1 Receptor Agonist Lixisenatide (Morning or Evening) in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin
ClinicalTrials.gov study NCT00712673. IPD Sharing: Not stated. Countries: 16. Publications: 4.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.